Nervgen Pharma NGEN
NASDAQ NGEN
$1.78 +0.02 (+1.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nervgen Pharma (NGEN) Net Income towards Common Stockholders (2025 - 2026)

Updated

Nervgen Pharma (NGEN) recorded Net Income towards Common Stockholders of -$21.12 million in the quarter ended Jun 30, 2026, compared with -$6.57 million a year earlier.

Analysis

Nervgen Pharma (NGEN) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends

On a TTM basis, Nervgen Pharma's Net Income towards Common Stockholders came in at -$26.16 million as of Jun 30, 2026; for the year ended Dec 31, 2025, it was -$31.58 million.

  • Across earlier years, Net Income towards Common Stockholders came in at -$17.71 million in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 5.53 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.61 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 2.89 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -10.50 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -248.00 Mn
10 Nervgen Pharma 141.78 Mn 141.78 Mn - -21.12 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -21.12 Mn
Mar 31, 2026 -1.22 Mn
Jun 30, 2025 -6.57 Mn
Mar 31, 2025 2.75 Mn
API Access

Nervgen Pharma Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=NGEN&period=max&api_key=YOUR_API_KEY